A manufacturing change is decided in Quality and filed by Regulatory. When the two are tracked in different systems, changes close before the filings they depend on are approved.
PMDA publishes its eCTD v4.0 validation rules as configuration. Reading them literally is not enough — some of the most important conditions exist only in the rule text.
A document can be placed in a sequence while it is still being written. That is useful. Publishing it in that state is not — and the system, not a checklist, should be what stops it.
Most submission defects are mechanical: fast web view, bookmark zoom, metadata, a link to the right document but the wrong page. Each is easy to fix — and expensive to find at the end.
“Current approved” is one of the most dangerous phrases in labeling. Which version was actually approved — and what changed between your proposal and the label the agency signed off?
PMDA explicitly permits reusing a document filed under a different application — under three conditions, one of which no publishing tool can check. What the software does about that gap is a design decision with real consequences.
You have found a stale hyperlink in a sequence you filed eighteen months ago. The correct fix is obvious. The correct place to write it is not the file you are looking at.
Promotional submissions go through the same FDA Electronic Submissions Gateway as everything else — but the account setup, the test submission, and OPDP’s own structural review are three separate lead times that teams routinely discover in the wrong order.
A grouped submission lets one promotional piece cover several applications at once. It is the biggest efficiency available in ad-promo publishing, and the easiest to get subtly wrong.
OPDP publishes the errors it sees most often in promotional eCTD submissions. Most are structural, most are silent, and several fail in ways that are not obvious from the rejection notice.